128 related articles for article (PubMed ID: 3656356)
21. Some new prospects in the mechanism of control of arachidonate metabolism in human placenta and amnion.
Dembélé-Duchesne MJ; Thaler-Dao H; Chavis C; de Paulet AC
Prostaglandins; 1981 Dec; 22(6):979-1002. PubMed ID: 6801732
[No Abstract] [Full Text] [Related]
22. Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses.
Hardee MM; Moore JN; Hardee GE
Res Vet Sci; 1986 Mar; 40(2):152-6. PubMed ID: 3517992
[TBL] [Abstract][Full Text] [Related]
23. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.
Fitzgerald DJ; Fragetta J; FitzGerald GA
J Clin Invest; 1988 Nov; 82(5):1708-13. PubMed ID: 3183064
[TBL] [Abstract][Full Text] [Related]
24. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
Vezza R; Mezzasoma AM; Venditti G; Gresele P
Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
[TBL] [Abstract][Full Text] [Related]
25. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
FitzGerald GA; Brash AR; Oates JA; Pedersen AK
J Clin Invest; 1983 Oct; 72(4):1336-43. PubMed ID: 6355181
[TBL] [Abstract][Full Text] [Related]
26. 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
Martinez GR; Walker KA; Hirschfeld DR; Bruno JJ; Yang DS; Maloney PJ
J Med Chem; 1992 Feb; 35(4):620-8. PubMed ID: 1311763
[TBL] [Abstract][Full Text] [Related]
27. Prostacyclin production in vascular endothelium of patients with Blackfoot disease.
Mak OT
Adv Exp Med Biol; 1988; 242():119-25. PubMed ID: 3072861
[TBL] [Abstract][Full Text] [Related]
28. Mechanism-based inactivation of thromboxane A2 synthase.
Fitzpatrick FA; Jones D; Winitz S; Fish HT
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():161-3. PubMed ID: 1825535
[No Abstract] [Full Text] [Related]
29. Biosynthesis and pharmacological modulation of thromboxane in humans.
Patrono C
Circulation; 1990 Jan; 81(1 Suppl):I12-5; discussion I22-3. PubMed ID: 2136814
[TBL] [Abstract][Full Text] [Related]
30. 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase.
Jacobs C; Frotscher M; Dannhardt G; Hartmann RW
J Med Chem; 2000 May; 43(9):1841-51. PubMed ID: 10794700
[TBL] [Abstract][Full Text] [Related]
31. Imidazol-1-yl and pyridin-3-yl derivatives of 4-phenyl-1,4-dihydropyridines combining Ca2+ antagonism and thromboxane A2 synthase inhibition.
Cozzi P; Carganico G; Fusar D; Grossoni M; Menichincheri M; Pinciroli V; Tonani R; Vaghi F; Salvati P
J Med Chem; 1993 Oct; 36(20):2964-72. PubMed ID: 8411014
[TBL] [Abstract][Full Text] [Related]
32. Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme.
Haurand M; Ullrich V
J Biol Chem; 1985 Dec; 260(28):15059-67. PubMed ID: 2999104
[TBL] [Abstract][Full Text] [Related]
33. Production of thromboxane and prostaglandins in human blood in the presence of thromboxane synthase inhibitors: a comparison of RIA and GC/MS determinations.
Weber C; Beetens JR; Van de Wiele R; Höller M; De Clerck F
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):7-15. PubMed ID: 1773000
[TBL] [Abstract][Full Text] [Related]
34. Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus.
De La Cruz JP; Moreno A; Ruiz-Ruiz MI; Sánchez De La Cuesta F
Thromb Res; 2000 Feb; 97(3):125-31. PubMed ID: 10680643
[TBL] [Abstract][Full Text] [Related]
35. Thromboxane synthase catalyses hydroxylations of prostaglandin H2 analogs in the presence of iodosylbenzene.
Hecker M; Baader WJ; Weber P; Ullrich V
Eur J Biochem; 1987 Dec; 169(3):563-9. PubMed ID: 3691505
[TBL] [Abstract][Full Text] [Related]
36. Effects of a sustained thromboxane synthase inhibition on exercise-induced changes in eicosanoid formation, catecholamine concentration, and platelet aggregation in humans.
Ohnishi A; Ishizaki T; Echizen H; Yasuda K; Fujiwara H; Tanaka T
Clin Pharmacol Ther; 1992 Apr; 51(4):454-64. PubMed ID: 1563215
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic effects of Wy 27569: a combined calcium channel blocker and thromboxane synthetase inhibitor.
Ennis C; Granger SE; Middlefell VC; Philpot ME; Shepperson NB
J Cardiovasc Pharmacol; 1989 Apr; 13(4):511-9. PubMed ID: 2470986
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
39. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis--effect of a thromboxane synthase inhibitor.
Carter AJ; Bevan JA; Hanley SP; Morgan WE; Turner DR
Thromb Haemost; 1984 Apr; 51(2):257-60. PubMed ID: 6377567
[TBL] [Abstract][Full Text] [Related]
40. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
